Covariate | Univariate analysis | Multivariate analysisa | ||
---|---|---|---|---|
RR (95% CI) | P | RR (95% CI) | P | |
Age ≥ 55 years | 1.50 (0.13–16.32) | 0.739 |  |  |
Male sex | 2.00 (0.29–13.51) | 0.477 |  |  |
Type of cancer, low risk vs. high/very high risk | 2.53 (0.37–17.24) | 0.341 |  |  |
Cancer stage, localized vs. advanced/metastasis | 0.88 (0.13–6.00) | 0.904 |  |  |
Chemotherapy regimen | ||||
 Cisplatin/carboplatin-based | 3.27 (0.47–22.46) | 0.228 | 0.454 (0.208–26.68) | 0.704 |
 Fluorouracil-based | 4.77 (0.48–46.90) | 0.182 | 1.309 (0.606–17.14) | 0.456 |
 Bevacizumab | 1.50 (0.13–16.32) | 0.739 |  |  |
 Anthracycline | 2.66 (0.22–32.17) | 0.440 |  |  |
 Use of steroids | 3.20 (0.24–42.18) | 0.377 |  |  |
Group O blood type | 0.77 (0.77–7.71) | 0.825 |  |  |
D-dimer ≥2320 ng/mL (75th percentile) | 2.55 (0.52–12.48) | 0.242 |  |  |
D-dimer ≥4622.4 ng/mL (90th percentile) | 3.57 (0.707–18.04) | 0.123 | 1.00 (0.99–2.01) | 0.900 |
High Khorana risk score | 8.07 (0.84–77.1) | 0.07 | 0.537 (0.121–13.65) | 0.537 |
Prechemotherapy sP-selectin ≥105.5 ng/mL | 11.67 (2.22–61.27) | 0.004 | 1.02 (0.98–11.05) | 0.260 |
Prechemotherapy vWF:Ag ≥ 2.35 IU/mL | 7.50 (1.53–36.71) | 0.013 | 3.80 (1.15–12.48) | 0.028 |
Prechemotherapy ADAMTS-13 ≤ 1.03 IU/mL | 13.5 (1.31–38.65) | 0.029 | 2.67 (1.22–23.82) | 0.005 |